ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.795,32
0,62%
S&P 500
5.214,08
0,00%
Dow Jones
39.387,76
0,00%
Euro vs US Dollar
1,0771
-0,10%
Bitcoin
62.908,52
-0,22%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Janux Therapeutics Inc (JANX)

  7. Janux Therapeutics Inc (JANX) News

JANX

Janux Therapeutics (JANX)

Janux Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:JANX
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202415h13Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:JANXJanux Therapeutics Inc
07/05/202422h01Business WireJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
08/03/202422h47Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
08/03/202422h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
08/03/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
08/03/202422h01Business WireJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
29/02/202423h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
29/02/202423h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
29/02/202407h22Business WireJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
29/02/202403h55Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:JANXJanux Therapeutics Inc
28/02/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
28/02/202403h50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
27/02/202423h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
27/02/202423h00Business WireJanux Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:JANXJanux Therapeutics Inc
26/02/202422h05Business WireJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsNASDAQ:JANXJanux Therapeutics Inc
20/02/202414h00Business WireJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008NASDAQ:JANXJanux Therapeutics Inc
09/02/202422h31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
01/02/202422h15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
08/01/202415h00Business WireJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerNASDAQ:JANXJanux Therapeutics Inc
03/01/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202422h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202422h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202422h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202422h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
03/01/202422h45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
07/11/202322h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:JANXJanux Therapeutics Inc
07/11/202322h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
07/11/202322h01Business WireJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
08/09/202300h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
14/08/202322h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JANX

Kürzlich von Ihnen besucht

USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US30
US 30
NYSE
JPM
JP Morgan Chase
TG
DBK
Deutsche Bank
AMEX
XLV
Health Care Select Sector
AMEX
XLE
Energy Select Sector SPDR
COIN
ETHUSD
Ethereum
COIN
SOLUSD
Solana
DBI
DAX
DAX
FX
EURUSD
Euro vs US Dollar
FX
EURJPY
Euro vs Yen
NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten